Recruiting

Observational StudyStorage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment

Sponsor:

Vanderbilt-Ingram Cancer Center

Code:

NCT01205815

Conditions

Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Tissue and blood collection

Study Details

Brief summary:

The purpose of this research is to identify biological characteristics occurring in the initiation and progression of melanoma.

Conditions

Melanoma

Study ID

NCT01205815

Start date

Jun 3, 2010

Status verified date

Mar, 2025

Completion date

Jun, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion criteria

Pathologically-proven diagnosis of melanoma.
Patient must have a test or procedure that has the potential to provide left-over tissue that can be banked for future research purposes OR the patient has already had a diagnostic or therapeutic procedure but who has not yet been approached to participate is also eligible.

Exclusion criteria

Any patient with significant contraindications to venipuncture (e.g., severe anemia) will be excluded from blood collection procedures. However, if the patient provides consent and a paraffin-embedded block or 10-15 unstained slides of their tissue diagnosis, they will not be excluded from this protocol.
Any patient unable or unwilling to provide consent.

Study Design

Enrollment

3000 participants

Anticipated

Interventions and Outcome Measures

Interventions

Tissue and blood collection

Tissue will be obtained from a previous biopsy if available, or if unavailable, tissue will be collected from a scheduled biopsy. About3-4 teaspoons of blood will be collected.

Primary outcome measure

Molecular changes in patients' melanoma tissue [ Time Frame: at 120 months ]

Central Contacts and Locations

Central contacts

Vanderbilt-Ingram Service for Timely Access

800-811-8480

Locations

Vanderbitl-Ingram Cancer Center

Recruiting

Nashville, Tennessee, United States

Contacts

Vanderbilt-Ingram Service for Timely Access

800-811-8480

Principal Investigator:

Douglas Johnson, MD

More Information

Sponsor

Vanderbilt-Ingram Cancer Center

Last update posted

Sep 19, 2025

Last verified

Mar, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Vanderbilt-Ingram Cancer Center on 2025-09-19.